Comparison Sitagliptin/Metformin combination therapy with metformin monotherapy in patients with type 2 diabetes mellitus

Authors

  • Reema Zidan Tishreen university
  • Ruba Salman Tishreen University
  • Ruba Hamdan Tishreen University

Abstract

Background: Type 2 diabetes mellitus(T2DM) is considered as an important cause of morbidity worldwide due to the increased risk for microvascular complications leading to poor outcome. Early initiation of sitagliptin with metformin might improve the final outcome of patients.   

Aim: The purpose of this study was to determine the effect of combination sitagliptin with metformin on glycemic control. In addition to, investigation alterations in serum lipids. 

Materials and Methods: This was a Randomized Controlled Trial involved 85 patients with T2DM at Endocrinology unit, Internal Medicine Department, Tishreen University Hospital, Lattakia, during the period between April 2021-April 2022. Patients were divided into two groups: group 1 received treatment with metformin (44 patients), and group 2 who received sitagliptin with metformin (44 patients).       

Results: Out of 85 patients, 36 were male and 49 were female, with mean age of the patients was 56.51±9.8. There was no significant difference between two groups regarding of age, gender, and height, whereas body mass index(BMI) was significantly higher in patients who received sitagliptin with metformin. The rate of BMI decreasing was 2.9% in sitagliptin with metformin group versus 1.5% in metformin group without significant difference. HbA1c was decreased significantly in two groups but the higher rate of changes was in combined treatment group (16.6% versus 11.4%), and target HbA1c was obtained in 72.7% of patients in combined treatment group versus 52.3% in metformin group. There was a significant decreasing in fasting and postprandial blood glucose in metformin group; 22.6% and 22.8% and in sitagliptin with metformin group; 32.1% and 36.2% respectively. There was a significant decreasing in triglyceride(TG), total cholesterol(TC), and low density lipoprotein(LDL) in metformin group; 9.7%, 10.3%, and 11.3% versus 13.1%, 13.47%, and 16.1% in sitagliptin with metformin group respectively. High density lipoprotein(HDL) was increased significantly in metformin group (48.95±9.08 after therapy versus 46±8.8 before therapy). Both treatments were well tolerated with mo incidence of hypoglycaemia or abdominal disorders.             

Conclusion: Initiation of sitagliptin with metformin in patients with T2DM is considered a valuable method in improving glycemic control and serum lipids with reducing the associated morbidity. 

Downloads

Published

2022-11-13

How to Cite

1.
زيدان ر, ربا سلمان, ربا حمدان. Comparison Sitagliptin/Metformin combination therapy with metformin monotherapy in patients with type 2 diabetes mellitus. Tuj-hlth [Internet]. 2022Nov.13 [cited 2024Apr.18];44(5):313-2. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/13496

Issue

Vol. 44 No. 5 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Master student researches

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.